他汀类药物对急性缺血性卒中患者尿激酶静脉溶栓临床疗效的影响OA北大核心CSTPCD
Effects of different doses of statins on clinical outcomes in patients with acute ischemic stroke who received intravenous urokinase thrombolysis
目的 探讨不同剂量他汀类药物对急性缺血性卒中(AIS)患者尿激酶静脉溶栓的临床疗效的影响.方法 基于一项前瞻性、多中心的大型研究——中国发病4.5 h内缺血性卒中的静脉溶栓登记研究(INTRECIS)数据库,回顾性分析经尿激酶静脉溶栓的898例AIS患者的临床资料.根据患者住院期间他汀类药物的用量分为不使用他汀组(132例)、常规剂量他汀组(591例)和强化剂量他汀组(175例).临床疗效评价指标包括14 d美国国立卫生研究院卒中量表(NIHSS)评分改善和90 d预后极好(改良Rankin 评分≤1分)率.安全性评价指标包括卒中复发、出血事件和90 d全因死亡率.结果 在调整基线特征(年龄、冠心病、糖尿病、房颤、收缩压、卒中发作到静脉溶栓时间、入院到静脉溶栓给药时间、既往抗血小板用药史、血糖、三甲医院治疗)的差异后,常规剂量他汀组和强化剂量他汀组入院到14 d的NIHSS评分改善、90 d预后极好率均优于不用他汀组(P<0.05);安全性结局指标的单因素与多因素分析结果显示,3组的卒中复发和出血事件比较差异均无统计学意义(P>0.05);3组90 d全因死亡率比较,不用他汀组(10.6%)明显高于常规剂量他汀组(2.0%)和强化剂量他汀组(2.9%)(P<0.01).结论 对于AIS尿激酶静脉溶栓的患者,强化剂量他汀类药物的使用可促进14 d NIHSS评分和近期预后改善,同时不增加卒中复发和出血事件的风险;他汀类药物使用有利于降低病死率.
Objective To investigate the effect of different doses of statins on the clinical efficacy and safety outcome of intravenous thrombolytic therapy of urokinase in patients with acute ischemic stroke(AIS).Methods Based on a large prospective,multicenter study,the Chinese Intravenous Thrombolysis Registry for AIS within 4.5 h of onset(INTRECIS)database,clinical data of 898 patients with urokinase intravenous thrombolysis for AIS were retrospectively analyzed.According to the amount of statin used during hospitalization,the patients were divided into 132 patients in no-statin group,591 patients in conventional statin group and 175 patients in intensive statin group.Clinical outcome measures included 14-day improvement in the National Institutes of Health Stroke Scale(NIHSS)and 90-day excellent prognosis(improved Rankin score≤1 point).Safety measures included recurrent stroke,bleeding events,and 90-day all-cause mortality.Results After adjusting for differences in baseline characteristics(age,coronary heart disease,diabetes,atrial fibrillation,systolic blood pressure,OTT,DNT,previous anti-plate use,blood glucose,and treatment in Class A hospitals),NIHSS scores improved at 14 days after admission and excellent prognosis at 90 days after admission in convention-dose and intensive statin groups were superior to those in no-statin group(P<0.05);Univariate and multivariate analysis of safety outcome indicators showed no statistically significant differences in stroke recurrence and bleeding events among the three groups(P>0.05);The 90-day all-cause mortality was significantly higher in no-statin group(10.6%)than in convention-dose statin group(2.0%)and intensive dose statin group(2.9%)(P<0.01).Conclusions In patients with AIS who were treated with intravenous urokinase thrombolytic therapy,intensive statin use was associated with improved 14-day NIHSS score and near-term prognosis without increasing the risk of stroke recurrence and bleeding events.Statin use is beneficial to reduce mortality.
王维姣;陈会生
解放军北部战区总医院神经内科,辽宁沈阳 110016
临床医学
他汀急性缺血性卒中尿激酶静脉溶栓预后
statinacute ischemic strokeurokinaseintravenous thrombolysisprognosis
《解放军医学杂志》 2024 (002)
152-158 / 7
This work was supported by the National Key Research and Development Program of China(2017YFC1308200) 国家重点研发计划(2017YFC1308200)
评论